Rockwell Medical Enters into 3-Year Product Purchase Agreement with Centers for Dialysis Care
October 03 2023 - 6:00AM
Business Wire
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a
healthcare company that develops, manufactures, commercializes, and
distributes a portfolio of hemodialysis products to dialysis
providers worldwide, today announced that the Company entered into
a three-year product purchase agreement with Centers for Dialysis
Care, Inc. ("CDC"), the largest non-profit, independent outpatient
dialysis provider in Northeast Ohio.
CDC provides in-center dialysis, home dialysis, training,
education support, and nutrition counseling to individuals with
kidney disease and kidney failure. As part of this long-term,
multi-million dollar product purchase agreement, which includes
supply and purchasing commitments, Rockwell Medical will be the
preferred supplier of liquid and dry acid and bicarbonate
hemodialysis concentrates and related accessories to CDC and its
nearly 20 facilities located throughout Northeastern Ohio.
"CDC is a leader in providing high-quality, patient-centered
kidney health care to all individuals with kidney disease," said
Tim Chole, Senior Vice President, Sales and Marketing at Rockwell
Medical. "We are honored to be entrusted by CDC to be the preferred
supplier of hemodialysis concentrates to their clinics and
positively impact the patients they serve through their kidney care
journey."
"This long-term product purchase agreement reflects our
confidence in Rockwell Medical as a supplier," said Michael
Humphrey, Director of Procurement at CDC. "Rockwell Medical is a
leader in the hemodialysis concentrates space and has built a
reputation of going above and beyond to deliver these life
sustaining products to organizations like ours so that we can focus
on what we do best—provide patient-centric care to individuals
living with end stage kidney disease on dialysis."
About Rockwell Medical Rockwell Medical, Inc. (Nasdaq:
RMTI) is a healthcare company that develops, manufactures,
commercializes, and distributes a portfolio of hemodialysis
products for dialysis providers worldwide. Rockwell Medical's
mission is to provide dialysis clinics and the patients they serve
with the highest quality products supported by the best customer
service in the industry. Rockwell is focused on innovative,
long-term growth strategies that enhance its products, its
processes, and its people, enabling the Company to deliver
exceptional value to the healthcare system and provide a positive
impact on the lives of hemodialysis patients. Hemodialysis is the
most common form of end-stage kidney disease treatment and is
typically performed at freestanding outpatient dialysis centers,
hospital-based outpatient centers, skilled nursing facilities, or
in a patient’s home. Rockwell Medical's products are vital to
vulnerable patients with end-stage kidney disease, and the Company
is relentless in providing unmatched reliability and customer
service. Rockwell Medical is the second largest supplier of acid
and bicarbonate concentrates for dialysis patients in the United
States and intends to become the leading global supplier of
hemodialysis concentrates. Certified as a Great Place to Work® in
2023, Rockwell Medical is Driven to Deliver Life-Sustaining
Dialysis Solutions™. For more information, visit
www.RockwellMed.com.
Forward-Looking Statements Certain statements in this
press release may constitute "forward-looking statements" within
the meaning of the federal securities laws. Words such as, "may,"
"might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "could," "can," "would," "develop," "plan,"
"potential," "predict," "forecast," "project," "intend," "look
forward to," "remain confident," “are determined,” “are on track,”
“are resolute in our vision,” "work to," "drive towards," “focused
on,” or the negative of these terms, and similar expressions, or
statements regarding intent, belief, or current expectations, are
forward looking statements. There can be no assurance that Rockwell
Medical will become the leading global supplier of hemodialysis
concentrates or maintain its customer relationships going forward.
While Rockwell Medical believes these forward-looking statements
are reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties (including, without
limitation, those set forth in Rockwell Medical's SEC filings),
many of which are beyond our control and subject to change. Actual
results could be materially different. Risks and uncertainties
include, but are not limited to those risks more fully discussed in
the "Risk Factors" section of our Annual Report on Form 10-K for
the year ended December 31, 2022, as such description may be
amended or updated in any future reports we file with the SEC.
Rockwell Medical expressly disclaims any obligation to update our
forward-looking statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231003627662/en/
Heather R. Hunter SVP, Chief Corporate Affairs Officer (248)
432-1362 IR@RockwellMed.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024